A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
This study is currently recruiting participants.
Verified March 2013 by Eisai Inc.
Study NCT01136733
Information provided by Eisai Inc.
First Received on May 26, 2010.
Last Updated on March 27, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
